ImmuPharma CEO Tim McCarthy shares latest developments with P140 platform, road ahead

Proactive - Interviews for investors

ImmuPharma PLC (AIM:IMM) CEO Tim McCarthy joined Stephen Gunnion in the Proactive studio to discuss the company’s recent groundbreaking developments in autoimmune disease treatment. He highlighted the progress made with their P140 platform, emphasising its potential to address multiple autoimmune diseases and transform patient care. McCarthy explained, “This is a breakthrough in a lot of different ways,” referencing recent preclinical findings that allow the identification and categorisation of autoimmune diseases, paving the way for personalised medicine. He also noted the significant interest in P140 from major pharmaceutical companies, underlining its potential to deliver effective treatment without adverse effects. Additionally, McCarthy shared updates from the JP Morgan and Biotech Showcase conferences, where these advancements were presented to key industry players. ImmuPharma’s focus in 2025 includes expanding its partnerships and delivering on its transformative pipeline. Stay tuned for more updates on ImmuPharma’s innovations in the biotech space. Visit Proactive’s YouTube channel for more videos, and don’t forget to like, subscribe, and turn on notifications for future content. #ImmuPharma #AutoimmuneDiseases #P140Platform #PersonalizedMedicine #Biotech #TimMcCarthy #PharmaceuticalInnovation #LupusTreatment #CIDP #HealthcareRevolution